aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Annie Njanja
July 25, 2024
Voice recognition is getting integrated in nearly all facets of modern living, but there remains a big gap: speakers of minority languages, and those with thick accents or speech disorders like stuttering are typically less able to use speech recognition tools that control applications, transcribe or automate tasks, among other functions.
Tobi Olatunji, founder and CEO of clinical speech recognition startup Intron Health, wants to bridge this gap. He claims that Intron is Africa’s largest clinical database, with its algorithm trained on 3.5 million audio clips (16,000 hours) from over 18,000 contributors, mainly healthcare practitioners, representing 29 countries and 288 accents. Olatunji says that drawing most of its contributors from the healthcare sector ensures that medical terms are pronounced and captured correctly for his target markets.
“Because we’ve already trained on many African accents, it’s very likely that the baseline performance of their access will be much better than any other service they use,” he said, adding that data from Ghana, Uganda and South Africa is growing, and that the startup is confident about deploying the model there.
Olatunji’s interest in health-tech stems from two strands of his experience. First, he got training and practiced as a medical doctor in Nigeria, where he saw first-hand the inefficiencies of the systems in that market, including how much paperwork needed to be filled out, and how hard it was to track all of it.
“When I was a doctor in Nigeria a couple years ago, even during medical school and even now, I get irritated easily doing a repetitive task that is not deserving of human efforts,” he said. “An easy example is we had to write a patient’s name on every lab order you do. And just something that’s simple, let’s say I’m seeing the patients, and they need to get some prescriptions, they need to get some labs. I have to manually write out every order for them. It’s just frustrating for me to have to repeat the patient name over and over on each form, the age, the date, and all that… I’m always asking, how can we do things better? How can we make life easier for doctors? Can we take some tasks away and offload them to another system so that the doctor can spend their time doing things that are very valuable?”
Those questions propelled him to the next phase of his life. Olatunji moved to the U.S. to pursue a initially a masters degree in medical informatics from the University of San Francisco and then another in computer science at Georgia Tech.
He then cut his teeth at a number of tech companies. As a clinical natural language programming (NLP) scientist and researcher at Enlitic, a San Francisco Bay Area company, he built models to automate the extraction of information from radiology text reports. He also served Amazon Web Services as a machine learning scientist. At both Enlitic and Amazon, he focused on natural language processing for healthcare, shaping systems that enable hospitals to run better.
Throughout those experiences, he started to form ideas around how what was being developed and used in the U.S. could be used to improve healthcare in Nigeria and other emerging markets like it.
The original aim of Intron Health, launched in 2020, was to digitize hospital operations in Africa through an Electronic Medical Record (EMR) System. But take-up was challenging: it turned out physicians preferred writing to typing, said Olatunji.
That led him to explore how to improve that more basic problem: how to make physicans’ basic data entry, writing, work better. At first the company looked at third-party solutions for automating tasks such as note taking, and embedding existing speech to text technologies into his EMR program.
There were a lot of issues, however, because of constant mis-transcription. It became clear to Olatunji that thick African accents and the pronunciation of complicated medical terms and names made the adoption of existing foreign transcription tools impractical.
This marked the genesis of Intron Health’s speech recognition technology, which can recognize African accents, and can also be integrated in existing EMRs. The tool has to date been adopted in 30 hospitals across five markets, including Kenya and Nigeria.
There have been some immediate positive outcomes. In one case, Olatunji said, Intron Health has helped reduce the waiting time for radiology results at one of West Africa’s largest hospitals from 48 hours to 20 minutes. Such efficiencies are critical in healthcare provision, especially in Africa, where the doctor to patient ratio remains one of the lowest in the world.
“Hospitals have already spent so much on equipment and technology…Ensuring that they apply these tech is important. We’re able to provide value to help them improve the adoption of the EMR system,” he said.
Looking ahead, the startup is exploring new growth frontiers backed by a $1.6 million pre-seed round, led by Microtraction, with participation from Plug and Play Ventures, Jaza Rift Ventures, Octopus Ventures, Africa Health Ventures, OpenseedVC, Pi Campus, Alumni Angel, Baker Bridge Capital and several angel investors.
In terms of technology, Intron Health is working to perfect noise cancelation, as well as ensuring that the platform works well even in low bandwidths. This is in addition to enabling the transcription of multi-speaker conversations, and integrating text-to-speech capabilities.
The plan, Olatunji says, is to add intelligence systems or decision support tools for tasks such as prescription or lab tests. These tools, he adds, can help reduce doctor errors, and ensure adequate patient care besides speeding up their work.
Intron Health is among the growing number of generative AI startups in the medical space, including Microsoft’s DAX Express, which are reducing administrative tasks for clinicians by generating notes within seconds. The emergence and adoption of these technologies come as the global speech and voice recognition market is projected to be valued at $84.97 billion by 2032, following a CAGR of 23.7% from 2024, according to Fortune Business Insights.
Beyond building voice technologies, Intron is also playing a pivotal role in speech research in Africa, having recently partnered with Google Research, the Bill & Melinda Gates Foundation, and Digital Square at PATH to evaluate popular Large Language Models (LLMs) such as OpenAI’s GPT-4o, Google’s Gemini, and Anthropic’s Claude across 15 countries, to identify strengths, weaknesses, and risks of bias or harm in LLMs. This is all in a bid to ensure that culturally attuned models are available for African clinics and hospitals.
Share:
Anthropic CEO says spies are after $100M AI secrets in a ‘few lines of code’
Anthropic’s CEO Dario Amodei is worried that spies, likely from China, are getting their hands on costly “algorithmic secrets” from the U.S.’s top AI companies — and he wants the U.S. government to step in. Speaking at a Council on Foreign Relations event on Monday, Amodei said that China is known for its “large-scale industrial espionage” and that AI companies like Anthropic are almost certainly being targeted. “Many of these algorithmic secrets, there are $100 million secrets that are a few l
Mar 12, 2025
Food delivery startup Wonder acquires media company Tastemade for $90M
Food delivery startup Wonder is acquiring media company Tastemade for around $90 million, according to The Wall Street Journal. Founded in 2021, Tastemade produces food, travel, and home videos and operates several free, ad-supported streaming television (FAST) channels. The acquisition gives Wonder access to a content studio, production company, and advertising business. Wonder will leverage all of these assets to promote its brands to a wider audience, the company says. The deal marks Wonder’
Mar 12, 2025
Donald Trump Jr. has been boosting MAGA-related startups
Since Donald Trump Jr. joined VC firm 1789 Capital after his father won the election, he’s been busy monetizing the Make America Great Again (MAGA) ecosystem. He’s been making bets in media, pharmaceutical, guns, and crypto while pushing against environmental, social, and governance (ESG) and diversity, equity, and inclusion (DEI), the Financial Times reported. The VC firm was co-founded by Trump donor Omeed Malik (who is also a backer of Substack) and has support from Rebekah Mercer, a backer
Mar 12, 2025
Don't miss our latest news and updates. Subscribe to the newsletter